|
1.
|
|
13 p, 938.1 KB |
Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain
/
Trigueros, Juan Antonio (Servicio de Salud de Castilla-La Mancha) ;
Garin, Noe (Institut d'Investigació Biomèdica Sant Pau) ;
Baloira, Adolfo (Hospital Universitario de Pontevedra) ;
Aceituno, Susana (Outcomes'10) ;
Calvo, Ana (Outcomes'10) ;
Prades, Miriam (Outcomes'10) ;
Touron, Carolina (AstraZeneca Farmacéutica España) ;
Martínez, Anisia (AstraZeneca Farmacéutica España) ;
Torres, Covadonga (AstraZeneca Farmacéutica España) ;
Universitat Autònoma de Barcelona
To evaluate the cost-effectiveness of Budesonide/Glycopyrronium/Formoterol (BUD/GLY/FOR) versus LAMA/LABA and ICS/ LABA, respectively, in patients with moderate to severe COPD, from the Spanish National Healthcare System (NHS) perspective. [...]
2022 -  10.2147/COPD.S384591
International journal of COPD, Vol. 17 (2022) , p. 2905-2917
|
|
|
2.
|
|
7 p, 715.4 KB |
Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting : Protocol for a phase IV, single-arm, open-label trial
/
Gil, Emilio (Ferrer Internacional. S.A.) ;
Garcia-Alonso, Fernando (Ferrer Internacional. S.A.) ;
Boldeanu, Anca (Ferrer Internacional. S.A.) ;
Baleeiro Teixeira, Thaïs (Ferrer Internacional. S.A.) ;
Tordera, Vicente (Hospital Lluís Alcanyis) ;
Viciedo, Ramón Palmer (Hospital Provincial de Castelló) ;
Salgado Serrano, Dr Purificación (Hospital del Mar (Barcelona, Catalunya)) ;
Domingo Ribas, Jordi (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Corripio, Iluminada (Institut d'Investigació Biomèdica Sant Pau) ;
Montes, José Manuel (Hospital Universitario Ramón y Cajal (Madrid)) ;
Lauffer, Javier Correas (Hospital Univ de Henares) ;
Murugarrem, Salvador Ruiz (Hospital Príncipe de Asturias) ;
García, Santiago Ovejero (Hospital Universitario Fundación Jiménez Díaz) ;
Mora, Fernando (Hospital Universitario Infanta Leonor) ;
López, Presentación Ataz (Complejo Hospitalario Torrecárdenas (Almeria)) ;
Navas, Andrés Fontalba (Hospital la Inmaculada) ;
Pinto, Ana Mª González (Hospital Santiago Apóstol) ;
Martínez, Ricardo (Hospital Virgen Del Mirón) ;
Castrillo, César García (Complejo Hospitalario de Jaen) ;
Toledo, Francisco (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Vieta, Eduard (Hospital Clínic i Provincial de Barcelona) ;
González, Emilio (Hermanas Hospitalarias Sociosanitario Palencia) ;
Franco Martín, Manuel (Complejo Asistencial Zamora) ;
Drasovean, Nicolae Virgil (Spitalul de Psihiatrie 'Elisabeta Doamna' Galati) ;
Dahl, Nils Hâvard (Helse Nord-Trøndelag HV Sykehuset Levanger) ;
Skagen, Bo (Spesialistesenteret På Straume-Helsesenteret) ;
Zilles, David (Klinik Für Psychiatrie und Psychotherapie der Universitätsmedizin Göttingen) ;
Zwanzger, Peter (Allgemeinpsychiatrie und Psychosomatik) ;
Juckel, Georg (LWL-Universitätsklinikum Bochum der Ruhr-Universität Bochum) ;
Kahl, Kai G. (Medizinische Hochschule Hannover) ;
Messer, Thomas (Fachklinik Für Psychiatrie) ;
Kasper, Siegfried (Medizinische Universität Wien Universitätsklinik Für Psychiatrie und Psychotherapie) ;
Universitat Autònoma de Barcelona
There is a need for fast-acting, non-injection antiagitation treatments that are well tolerated and can be used outside of healthcare facilities. In phase II/III trials, an inhaled formulation of loxapine (ADASUVE®), a well-established, first-generation antipsychotic agent, provided rapid control of mild to moderate agitation in the hospital setting. [...]
2018 - 10.1136/bmjopen-2017-020242
BMJ open, Vol. 8 Núm. 10 (january 2018) , p. e020242
|
|
|
3.
|
|
23 p, 3.1 MB |
Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations : SABINA Findings From Europe and North America
/
Quint, Jennifer K. (Imperial College London) ;
Arnetorp, Sofie (Payer Analytics. AstraZeneca) ;
Kocks, Janwillem W.H. (University Medical Center Groningen) ;
Kupczyk, Maciej (Karolinska Institutet (Estocolm, Suècia)) ;
Nuevo, Javier (Evidence Generation. AstraZeneca) ;
Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau) ;
Cabrera, Claudia (BioPharmaceuticals Medical (Evidence). AstraZeneca) ;
Raherison-Semjen, Chantal (Bordeaux University) ;
Walker, Brandie (University of Calgary) ;
Penz, Erika (University of Saskatchewan) ;
Gilbert, Ileen (Medical Affairs. AstraZeneca) ;
Lugogo, Njira Lucia (University of Michigan) ;
van der Valk, Ralf J.P. (Medical Affairs. AstraZeneca) ;
Fong, Andrew ;
Qian, Christina ;
Fabry-Vendrand, Caroline ;
Touboul, Chantal ;
Brzostek, Dorota ;
Maslova, Ekaterina ;
Surmont, Filip ;
Goike, Helena ;
Gandhi, Hitesh ;
Korevaar, J.C. ;
Tkacz, Joseph ;
Johnston, Karissa ;
Peres da Costa, Keith ;
van Dijk, L. ;
Vervloet, M. ;
Pollack, Michael ;
Hernandez, Paul ;
Boarino, S. ;
Noorduyn, Stephen G. ;
Beekman-Hendricks, Wendy ;
Weesie, Y.M. ;
Universitat Autònoma de Barcelona
Expert national/global asthma management recommendations raise the issue whether a safe threshold of short-acting beta-2 agonist (SABA) use without concomitant inhaled corticosteroids (ICS) exists. To examine SABA and maintenance therapy associations with severe asthma exacerbations across North America and Europe. [...]
2022 - 10.1016/j.jaip.2022.02.047
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10 Núm. 9 (september 2022) , p. 2297-2309.e10
|
|
|
4.
|
|
14 p, 2.5 MB |
Consensus on mild asthma management : results of a modified Delphi study
/
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Garcia, Gabriel (Hospital Rodolfo Rossi) ;
Gemicioglu, Bilun (Istanbul University-Cerrahpasa) ;
Van, Giap Vu (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias) ;
Larenas-Linnemann, Désirée (Clinical Foundation and Hospital) ;
Neffen, Hugo (Centro de Alergia e Inmunología y Enfermedades Respiratorias) ;
Poachanukoon, Orapan (Thammasat University Hospital) ;
Sagara, Hironori (Showa University School of Medicine) ;
Berend, Norbert (Respiratory Franchise) ;
Pizzichini, Emilio (Respiratory Franchise) ;
Irusen, Elvis (GlaxoSmithKline Biologicals) ;
Aggarwal, Bhumika (European Respiratory Society (ERS)) ;
Eken, Volkan (Laboratorios Almirall, S.A.) ;
Levy, Gur (GlaxoSmithKline) ;
Universitat Autònoma de Barcelona
OBJECTIVE: In order to understand the role of regular controller inhaled corticosteroids (ICS) versus as-needed ICS-formoterol in managing mild asthma, we performed a modified Delphi procedure. METHODS: Opinions from 16 respiratory experts to three surveys and during a virtual scientific workshop helped to develop final consensus statements (pre-defined as 70% agreement). [...]
2022 - 10.1080/02770903.2022.2034850
Journal of Asthma, 2022, p. 1-13
|
|
|
5.
|
|
12 p, 330.8 KB |
A new Therapeutic approach based on a reinterpretation of asthma control
/
Pérez de Llano, Luis (Hospital Universitario de Lucus Augusti, EOXI Lugo) ;
Entrenas, Luis Manuel (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Carrascosa, M. Inés (Hospital de Urduliz Alfredo Espinosa) ;
Dávila, Ignacio (Hospital Clínico Universitario (Salamanca)) ;
Almonacid, Carlos (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Abascal-Bolado, Beatriz (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Montoro, Francisco Javier (Hospital de Llíria, Valencia;) ;
Sogo, Ana Isabel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
The concept of asthma control is fundamental because it establishes a target for treatment, but despite the diversity of definitions, a high proportion of patients fail to achieve it. In this article, we highlight the shortcomings of the current concept of control by discussing aspects such as the differences between patient- and physician-perceived control and the limitations of the tools used to assess it. [...]
2023 - 10.23866/BRNRev:2023-M0089
BRN Review, Vol. 9 Núm. 2 (2023)
|
|
|
6.
|
|
11 p, 3.7 MB |
Inhaled amikacin for pneumonia treatment and dissemination prevention : an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
/
Motos, Ana (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias) ;
Yang, Hua (Universitat de Barcelona) ;
Li Bassi, Gianluigi (Critical Care Research Group, The Prince Charles Hospital, University of Queensland, Queensland University of Technology, UnitingCare Hospitals, Wesley Medical Research, Brisbane, Australia) ;
Yang, Minlan (Universitat de Barcelona) ;
Meli, Andrea (Università degli Studi di Milano) ;
Battaglini, Denise (San Martino Policlinico Hospital) ;
Cabrera, Roberto (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias) ;
Bobi, Joaquim (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Pagliara, Francesco (IRCCS for Oncology and Neurosciences. Anesthesia and Critical Care, San Martino Policlinico Hospital) ;
Frigola, Gerard (Hospital Clínic i Provincial de Barcelona) ;
Camprubí-Rimblas, Marta (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Fernández-Barat, Laia (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias) ;
Rigol, Montserrat (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ferrer-Segarra, Antoni (Parc de Salut MAR de Barcelona) ;
Kiarostami, Kasra (Universitat de Barcelona) ;
Martinez, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Nicolau, David P. (Hartford Hospital) ;
Artigas Raventós, Antoni (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Pelosi, Paolo (Università degli Studi di Genova) ;
Vila, Jordi (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas) ;
Torres, Antoni (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias) ;
Universitat Autònoma de Barcelona
Pseudomonas aerugino sa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. [...]
2023 - 10.1186/s13054-023-04331-x
Critical Care, Vol. 27 (february 2023)
|
|
|
7.
|
|
14 p, 2.0 MB |
Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis : A Systematic Review and a Network Meta-Analysis
/
Tejada, Sofia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramírez-Estrada, Sergio (Clínica Corachán. Intensive Care Department) ;
Forero, Carlos G. (Universitat Internacional de Catalunya) ;
Gallego, Miguel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Soriano, Joan B.. (Universidad Autónoma de Madrid) ;
Cardinal-Fernández, Pablo A. (HM Group (Madrid)) ;
Ehrmann, Stephan (Université de Tours. Centre d'étude des Pathologies Respiratoires) ;
Rello, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca)
It remains unknown whether the type of aerosol generating device is affecting efficacy and safety among non-cystic fibrosis bronchiectasis (NCFB) adults. The proposal of this network meta-analysis (NMA) is to evaluate effectiveness and safety of inhaled antibiotics administered via dry powder inhaler (DPI) and via nebulizers (SVN) among adult patients with NCFB. [...]
2022 - 10.3390/antibiotics11020275
Antibiotics, Vol. 11 Núm. 2 (february 2022)
|
|
|
8.
|
|
11 p, 594.6 KB |
A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
/
Miravitlles, Marc (Hospital Universitari Vall d'Hebron) ;
Cosio, Borja G.. (Institut d'Investigació Sanitària Illes Balears) ;
Arnedillo, Aurelio (Universidad de Cádiz) ;
Calle Rubio, Myriam (Universidad Complutense de Madrid) ;
Alcázar-Navarrete, Bernardino (Hospital de Alta Resolución de Loja) ;
González, Cruz (Hospital Clínic Universitari (València)) ;
Esteban, Cristóbal (Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas) ;
Trigueros, Juan Antonio (Centro de Salud Menasalbas) ;
Rodríguez González-Moro, José Miguel (Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Madrid)) ;
Quintano Jiménez, José Antonio (Centro de Salud Lucena I, Lucena, Córdoba, Spain) ;
Baloira, Adolfo (Complejo Hospitalario Universitario de Pontevedra) ;
Universitat Autònoma de Barcelona
According to the current clinical practice guidelines for chronic obstructive pulmonary disease (COPD), the addition of inhaled corticosteroids (ICS) to long-acting β agonist therapy is recommended in patients with moderate-to-severe disease and an increased risk of exacerbations. [...]
2017 - 10.1186/s12931-017-0682-y
Respiratory Research, Vol. 18 (november 2017)
|
|
|
9.
|
|
8 p, 665.5 KB |
Neumonías adquiridas en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica tratados con corticoides inhalados u otros broncodilatadores. Estudio PNEUMOCORT
/
Morros, Rosa (Universitat Autònoma de Barcelona) ;
Vedia Urgell, Cristina (Universitat Autònoma de Barcelona) ;
Giner-Soriano, Maria (Universitat Autònoma de Barcelona) ;
Casellas, Aina (Barcelona Institute for Global Health (ISGlobal)) ;
Amado, Ester (Institut Català de la Salut) ;
Baena Díez, José Miguel (Institut Català de la Salut)
Analizar el riesgo de neumonía y/o exacerbaciones en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) tratados con corticoides inhalados (CI) y no tratados con CI (NCI). Estimar el riesgo de neumonía según la dosis de CI. [...]
To analyse the risk of pneumonia and/or exacerbations in patients with chronic obstructive pulmonary disease (COPD) who receive treatment with inhaled corticosteroids (CI), in comparison with those who are not treated with inhaled corticosteroids (NCI). [...]
2019 - 10.1016/j.aprim.2018.02.007
Atencion Primaria, Vol. 51 Núm. 6 (june 2019) , p. 333-340
|
|
|
10.
|
|
14 p, 1.0 MB |
Withdrawal of inhaled corticosteroids in COPD patients : Rationale and algorithms
/
Avdeev, S. (Clinical Department. Federal Pulmonology Research Institute. Federal Medical and Biological Agency of Russia) ;
Aisanov, Z. (Department of Pulmonology. N.I. Pirogov Russian State National Research Medical University) ;
Arkhipov, V. (Department of Clinical Pharmacology and Therapy. Russian Medical Academy of Continuous Professional Education) ;
Belevskiy, A. (Department of Pulmonology. N.I. Pirogov Russian State National Research Medical University) ;
Leshchenko, I. (Department of Phthisiology. Pulmonology and Thoracic Surgery. Ural State Medical University) ;
Ovcharenko, S. (Department of Internal Diseases No.1. I.M. Sechenov First Moscow State Medical University) ;
Shmelev, E. (Department of Differential Diagnostics. Federal Central Research Institute of Tuberculosis) ;
Miravitlles, Marc. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Observational studies indicate that overutilization of inhaled corticosteroids (ICS) is common in patients with chronic obstructive pulmonary disease (COPD). Overprescription and the high risk of serious ICS-related adverse events make withdrawal of this treatment necessary in patients for whom the treatment-related risks outweigh the expected benefits. [...]
2019 - 10.2147/COPD.S207775
International journal of COPD, Vol. 14 (2019) , p. 1267-1280
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
